Clinical Trial Update: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pharmacokinetics, efficacy, safety, and tolerability of a combination therapy (simeprevir, daclatasvir, ribavirin) in recurrent chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2018-11-21